The acquisition positions Sanuwave to address the complete advanced wound care patient pathway from the start of the treatment to closure. Credit: CommsEditors101 / Pixabay.

Sanuwave Health has completed the acquisition of the wound care assets of the clinical-stage cell therapeutics company Celularity, including its UltraMIST Ultrasound Healing Therapy assets.

Sanuwave has also obtained the partnership rights for Celularity’s wound care biologic products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition enables the company to expand its addressable market and bring together energy transfer technologies and biologic skin substitute products to offer an end-to-end product offering platform in the advanced wound care market.

Additionally, the deal is expected to enable Sanuwave to address the complete advanced wound care patient pathway from the start of the treatment to closure.

Moreover, the treatment combination of the UltraMIST and the dermaPACE System is expected to demonstrate improved patient outcomes compared to the existing standard of care, initially for diabetic foot ulcers, and later, for all wound indications.

Sanuwave funded the acquisition through a mix of funded term debt, seller note and equity in the form of a private placement.

The private placement generated gross proceeds of $24m through the issuance of 119,125,000 shares of common stock and accompanying warrants with shares priced at $0.20 each, noted the company.

While existing investors and insiders acquired over 60% of the private placement, the remainder was purchased by healthcare-focused institutional and accredited investors.

HC Wainwright & Co acted as the exclusive placement agent for the private placement, while Lake Street Capital Markets acted as the financial advisor for the acquisition and the private placement.

William Blair & Company was the sole placement agent of debt financing.

In 2011, Sanuwave presented positive data from the Phase III clinical trial of dermaPACE used as a treatment for diabetic foot ulcers.